Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine

Ann M Miller; Steven M Varga

doi:10.1016/j.xcrm.2023.101081

Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine

Cell Rep Med. 2023 Jun 20;4(6):101081. doi: 10.1016/j.xcrm.2023.101081.

Authors

Ann M Miller¹, Steven M Varga²

Affiliations

¹ Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
² Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA. Electronic address: steven.varga@stjude.org.

Abstract

In this phase 3 trial, Kampmann et al.¹ demonstrated safety and efficacy of a maternal bivalent RSV prefusion F vaccine. Vaccine efficacy was achieved in reducing severe RSV-associated lower respiratory tract infections in infants at 90 and 180 days following birth.

Publication types

Clinical Trial, Phase III

MeSH terms

Antibodies, Neutralizing
Antibodies, Viral
Humans
Infant
Respiratory Syncytial Virus Infections* / prevention & control
Respiratory Syncytial Virus Vaccines* / adverse effects
Respiratory Syncytial Virus, Human*

Substances

Antibodies, Neutralizing
Antibodies, Viral
Respiratory Syncytial Virus Vaccines